Aurora Cannabis (TSX:ACB) Revenues Disrupt Cannabis Stocks

Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) expects to report an 81% increase in Q4 net revenues.

| More on:
edit Businessman using calculator next to laptop

Image source: Getty Images.

Mark your calendars. Aurora Cannabis (TSX:ACB)(NYSE:ACB) will release official fourth-quarter earnings on September 15. The stock should bounce when the company announces record revenues.

On Tuesday, Aurora released preliminary estimates of quarterly net revenue above $100 million for the fourth quarter ended June 30. Fiscal year revenue estimates total over $250 million — a substantial increase from 2018.

Aurora tracks company performance based on gross margins, kilograms of cannabis sold, and cash costs per gram produced. Shareholders can expect the yearly report to highlight the data surrounding these measures. Preliminary cannabis production figures hint at annual sales of nearly 30,000 kg.

Although growth and investment remain the number one priority, Aurora will soon integrate positive adjusted EBITDA from cannabis operations into the company’s key performance goals. Last year, Aurora announced adjusted EBITDA of negative $205.82 million.

Aurora Cannabis

Aurora Cannabis is Canada’s top cannabis cultivator and distributor with an expansive business network throughout the European Union. To date, Aurora operates under 17 subsidiaries including Aurora Deutschland, MED Colombia, and Chemi Pharmaceutical.

Aurora’s expansive international reach and strategic partnerships distinguish it from its competitors. In fact, Aurora already has exclusive partnerships with pharmacies in Germany and the U.K. to sell medical marijuana by prescription.

Moreover, top cannabis innovators, such as Capcium, Evio Beauty Group, and Wagner Dimas, have partnered with Aurora to develop quality cannabis brands.


Capcium is a market leader in softgel encapsulation of cannabis extracts, providing pharmaceutical-grade manufacturing to the cannabis industry. Aurora launched softgel capsules for both medical and adult-use cannabis markets at the end of 2018 under the CanniMed brand.

The softgel capsules contain equal proportions of CBD and THC in a six mg discrete pill format. The tablets are designed to balance the effects of CBD and THC and produce a long-lasting and enjoyable experience.

Evio Beauty

In partnership with Evio Beauty, Aurora Cannabis produces the cannabis skincare brand, Evio Skin. Products in the EvioSkin/Aurora Cannabis Collection include a hemp seed oil rejuvenating mask, hemp fibre wipes, and Omega 3-6-9 revitalizing serum. The partnership gives Aurora Cannabis access to high-end cosmetics consumers through popular Sephora retail outlets.

The skincare line also gives Aurora a brand-recognition advantage among female consumers who shop directly through Evio gives a mention to the Aurora Cannabis brand under every EvioSkin product listed on the website.

Wagner Dimas

Aurora Cannabis announced a partnership with Wagner Dimas in the summer of 2018. That summer marked Aurora Cannabis’s entrance into high-margin products.

The association granted Aurora Cannabis exclusive licence over Wagner’s “pre-roll” technology. Wagner Dimas developed ground-breaking technology to mass-produce pre-filled cannabis cigarettes. Pre-roll styles go beyond traditional cigarette-style rolls — cone-shaped and cigar-sized options are best sellers among California and Las Vegas adult-use consumers.

Foolish takeaway

Aurora Cannabis is a real winner on the Toronto Stock Exchange. The stock’s market value may be below that of Canopy Growth, but day trading in cannabis stocks has left many of the cannabis stocks mispriced.

Aurora Cannabis trades at 80% of Canopy Growth’s price, even though Aurora’s equity and net receivables are growing at a much faster rate. For these reasons, investors should consider investing in shares of Aurora Cannabis — a stock left severely neglected during the cannabis speculation-palooza.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Debra Ray has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »